Drug Profile
Aspirin/pantoprazole - GSK
Latest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiplatelets; Antipyretics; Antirheumatics; Antiulcers; Gastric antisecretories; Nonsteroidal anti-inflammatories; Salicylic acids; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors; Proton pump inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 12 Jul 2013 GlaxoSmithKline plans a phase I trial in Healthy volunteers in India (NCT01847404)
- 01 Jul 2013 Preclinical trials in NSAID-induced ulcer in India (PO)
- 31 May 2013 GlaxoSmithKline completes a phase I trial in healthy volunteers in India (NCT01847404)